Premium
Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3
Author(s) -
Smith Matthew L.,
Arch Rachael,
Smith LanLan,
Bainton Nigel,
Neat Michael,
Taylor Claire,
Bonnet Dominique,
Cavenagh Jamie D.,
Andrew Lister T.,
Fitzgibbon Jude
Publication year - 2005
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2004.05324.x
Subject(s) - cebpa , neuroblastoma ras viral oncogene homolog , ptpn11 , mutation , cytogenetics , gene mutation , medicine , fms like tyrosine kinase 3 , myeloid leukemia , genetics , oncology , cancer research , biology , gene , chromosome , kras
Summary A study was undertaken to develop an acute myeloid leukaemia (AML) screening panel to uncover novel recurring gene mutations. Analysis was performed on six genes known to be mutated in AML ( RUNX1 , FLT3 , KIT , CEBPA , PTPN11 and NRAS ) and an additional two candidate genes ( CCND3 and FES ) in a panel of 175 primary human AML samples that included all French–American–British types except M3, and all cytogenetic risk groups. One hundred and fifteen mutations were identified in 97 (55%) patients comprising 81 patients (46%) with one mutation, 14 patients (8%) with two mutations and two patients (1%) with three mutations. Fifty‐five of 88 (63%) patients with normal karyotype AML had at least one mutation. Correlation was observed between KIT mutation and ‘favourable risk’ cytogenetics ( P < 0·001), CEBPA mutation and ‘intermediate risk’ cytogenetics ( P = 0·045), and PTPN11 mutation and ‘poor risk’ disease ( P < 0·001). The frequency of individual gene mutation was in accordance with previously published studies. Three novel mutations of FLT3 were detected (Y589D, D839G, Y842H) that would have been overlooked by conventional gel electrophoresis. A 51‐bp deletion was detected in CCND3 in a patient with normal karyotype AML. This validated panel now provides an important tool to evaluate other candidate genes in the genesis of myeloid malignancy.